ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

ClinicalTrials.gov ID: NCT02584855

Public ClinicalTrials.gov record NCT02584855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Study identification

NCT ID
NCT02584855
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
394 participants

Conditions and interventions

Interventions

  • Ixekizumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 13, 2015
Primary completion
Oct 29, 2018
Completion
Oct 29, 2018
Last update posted
Nov 14, 2019

2015 – 2018

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Arizona Arthritis & Rheumatology Research Glendale Arizona 85306
Arizona Arthritis & Rheumatology Research, PLLC Mesa Arizona 85202
Arizona Arthritis Research, PLC Phoenix Arizona 85032
University of California, Davis - Health Systems Sacramento California 95817
East Bay Rheumatology Medical Group San Leandro California 94578
Arthritis & Osteoporosis Treatment Center, PA Orange Park Florida 32073
Florida Medical Clinic PA Zephyrhills Florida 33542
Physicians Clinic of Iowa Cedar Rapids Iowa 54203
Heartland Research Associates Wichita Kansas 67207
Klein and Associates MD, PA Cumberland Maryland 21502
Klein and Associates MD, PA Hagerstown Maryland 21740
University of Massachusetts Medical Center Worcester Massachusetts 01605
Glacier View Research Institute Kalispell Montana 59901
Arthritis, Rheumatic & Back Disease Associates Voorhees Township New Jersey 08043
Weill Cornell Physicians at Brooklyn Heights Brooklyn New York 11201
Robert A. Harrell, III, MD Durham North Carolina 27704
Pennsylvania Regional Center for Arthritis & Osteoarthritis Wyomissing Pennsylvania 19610
Pioneer Research Solutions Cypress Texas 77429
Arthritis Care & Diagnostic Center P.A. Dallas Texas 75231
Kadlec Clinic Rheumatology Kennewick Washington 99336
Seattle Rheumatology Associates, P.L.L.C. Seattle Washington 98122
Arthritis Northwest Rheumatology Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02584855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 14, 2019 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02584855 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →